glucagon receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-12. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Critics considered the order an effort to intimidate ICC civil servants from proceeding with its investigation and accused the administration of targeting the two prosecutors, both of African origin, based on their race. The U.S. District Court for the Southern District of New York granted a preliminary injunction blocking the sanctions in January 2021, through a challenge to the order brought by four dual-national American law professors and the Open Society Justice Initiative. (The Biden administration lifted the ICC sanctions in April 2021.) Also in September 2020, Trump used the IEEPA to order the removal of social media platforms TikTok and WeChat from U.S. app stores as well as prohibit domestic business transactions involving their respective China-based parent companies ByteDance and Tencent; the restrictions would have become applicable to TikTok unless it was sold to an American company within 45 days of the executive order's issuance. Observers (including Trump administration critics and many TikTok users) raised First Amendment concerns with the executive order and suggested that, while national security concerns were cited to justify them, the sanctions were prompted by the administration's hostile relations toward China in general and retaliation against TikTok in particular. This retaliation was claimed to be for certain anti-Trump content hosted by the app.
According to Venter, the composition of fatty acids in crocodile oil compared those found in human skin oil indicated that the palmitoleic acid (6%), oleic acid (39%), and linoleic acid (20%) in crocodile oil showed higher percentage than in human skin oil.
=== Hormone claim retracted === Although the original cytokine function of PBEF has not been confirmed to date, others have since reported or suggested a cytokine-like function for this protein. In particular, Nampt/PBEF was recently re-identified as a "new visceral fat-derived hormone" named visfatin. It is reported that visfatin is enriched in the visceral fat of both humans and mice and that its plasma levels increase during the development of obesity. Noteworthy is that visfatin is reported to exert insulin-mimetic effects in cultured cells and to lower plasma glucose levels in mice by binding to and activating the insulin receptor. However, the physiological relevance of visfatin is still in question because its plasma concentration is 40 to 100-fold lower than that of insulin despite having similar receptor-binding affinity. In addition, the ability of visfatin to bind and activate the insulin-receptor has yet to be confirmed by other groups. On 26 October 2007, A. Fukuhara (first author), I.Shimomura (senior author) and the other co-authors of the paper, who first described Visfatin as a visceral-fat derived hormone that acts by binding and activating the insulin receptor, retracted the entire paper at the suggestion of the editor of the journal 'Science' and recommendation of the Faculty Council of Osaka University Medical School after a report of the Committee for Research Integrity.
Agarose gel can have high gel strength at low concentration, making it suitable as an anti-convection medium for gel electrophoresis. Agarose gels as dilute as 0.15% can form slabs for gel electrophoresis. The agarose polymer contains charged groups, in particular pyruvate and sulfate. These negatively charged groups can slow down the movement of DNA molecules in a process called electroendosmosis (EEO). Low EEO (LE) agarose is therefore generally preferred for use in agarose gel electrophoresis of nucleic acids. Zero EEO agaroses are also available but these may be undesirable for some applications as they may be made by adding positively charged groups that can affect subsequent enzyme reactions. Electroendosmosis is a reason agarose is used preferentially over agar as agaropectin in agar contains a significant amount of negatively charged sulphate and carboxyl groups. The removal of agaropectin in agarose substantially reduces the EEO, as well as reducing the non-specific adsorption of biomolecules to the gel matrix. However, for some applications such as the electrophoresis of serum protein, a high EEO may be desirable, and agaropectin may be added in the gel used. LE agarose is said to be better for preparative electrophoresis, i.e. when DNA needs to be extracted from an agarose gel.
Sources: en.wikipedia.org
== Selected publications == Schneiderman, E.; Stalcup, A. M. (9 January 2001). "ChemInform Abstract: Cyclodextrins: A Versatile Tool in Separation Science". ChemInform. 32 (2): no. doi:10.1002/chin.200102265. ISSN 0931-7597. Vaher, M; Koel, M; Kaljurand, M (2002). "Application of 1-alkyl-3-methylimidazolium-based ionic liquids in non-aqueous capillary electrophoresis". Journal of Chromatography A. 979 (1–2): 27–32. doi:10.1016/s0021-9673(02)01499-1. ISSN 0021-9673. PMID 12498230. Stalcup, Apryll M.; Gahm, Kyung H. (1996). "Application of Sulfated Cyclodextrins to Chiral Separations by Capillary Zone Electrophoresis". Analytical Chemistry. 68 (8): 1360–1368. doi:10.1021/ac950764a. ISSN 0003-2700. PMID 8651498.
Brown fat or brown adipose tissue (BAT) is a specialized form of adipose tissue important for adaptive thermogenesis in humans and other mammals. BAT can generate heat by "uncoupling" the respiratory chain of oxidative phosphorylation within mitochondria through tissue-specific expression of uncoupling protein 1 (UCP1). BAT is primarily located around the neck and large blood vessels of the thorax, where it may effectively act in heat exchange. BAT is robustly activated upon cold exposure by the release of catecholamines from sympathetic nerves that results in UCP1 activation. Nearly half of the nerves present in adipose tissue are sensory neurons connected to the dorsal root ganglia. BAT activation may also occur in response to overfeeding. UCP1 activity is stimulated by long chain fatty acids that are produced subsequent to β-adrenergic receptor activation. UCP1 is proposed to function as a fatty acid proton symporter, although the exact mechanism has yet to be elucidated. In contrast, UCP1 is inhibited by ATP, ADP, and GTP. Attempts to simulate this process pharmacologically have so far been unsuccessful. Techniques to manipulate the differentiation of "brown fat" could become a mechanism for weight loss therapy in the future, encouraging the growth of tissue with this specialized metabolism without inducing it in other organs. A review on the eventual therapeutic targeting of brown fat to treat human obesity was published by Samuelson and Vidal-Puig in 2020.
Creatine transporter deficiency (CTD) is an inborn error of creatine metabolism in which creatine is not properly transported to the brain and muscles due to defective creatine transporters. CTD is an X-linked disorder caused by mutation in SLC6A8. SLC6A8 is located at Xq28. Hemizygous males with CTD express speech and behavior abnormalities, intellectual disabilities, development delay, seizures, and autistic behavior. Heterozygous females with CTD generally express fewer, less severe symptoms. CTD is one of three different types of cerebral creatine deficiency (CCD). The other two types of CCD are guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency. Clinical presentation of CTD is similar to that of GAMT and AGAT deficiency. CTD was first identified in 2001 with the presence of a hemizygous nonsense change in SLC6A8 in a male patient.
The I1 receptor appears to be a G protein-coupled receptor that is localized on the plasma membrane. It may be coupled to PLA2 signalling and thus prostaglandin synthesis. In addition, activation inhibits the sodium-hydrogen antiporter and enzymes of catecholamine synthesis are induced, suggesting that the I1 receptor may belong to the neurocytokine receptor family, since its signaling pathways are similar to those of interleukins. It is found in the neurons of the reticular formation, the dorsomedial medulla oblongata, adrenal medulla, renal epithelium, pancreatic islets, platelets, and the prostate. They are notably not expressed in the cerebral cortex or locus coeruleus. Animal research suggests that much of the antihypertensive action of imidazoline drugs such as clonidine is mediated by the I1 receptor. In addition, I1 receptor activation is used in ophthalmology to reduce intraocular pressure. Other putative functions include promoting Na+ excretion and promoting neural activity during hypoxia.
== Structure == The structure and properties of graphite oxide depend on the particular synthesis method and degree of oxidation. It typically preserves the layer structure of the parent graphite, but the layers are buckled and the interlayer spacing is about two times larger (~0.7 nm) than that of graphite. Strictly speaking "oxide" is an incorrect but historically established name. Besides epoxide groups (bridging oxygen atoms), other functional groups found experimentally are: carbonyl (C=O), hydroxyl (-OH), phenol and for graphite oxides prepared using sulphuric acid (e.g. Hummers method) some impurity of sulphur is often found, for example in a form of organosulfate groups. The detailed structure is still not understood due to the strong disorder and irregular packing of the layers. Graphene oxide layers are about 1.1 ± 0.2 nm thick. Scanning tunneling microscopy shows the presence of local regions where oxygen atoms are arranged in a rectangular pattern with lattice constant 0.27 nm × 0.41 nm. The edges of each layer are terminated with carboxyl and carbonyl groups. X-ray photoelectron spectroscopy shows the presence of several C1s peaks, their number and relative intensity depending on the particular oxidation method used. Assignment of these peaks to certain carbon functionalization types is somewhat uncertain and still under debate. For example, one interpretation goes as follows: non-oxygenated ring contexts (284.8 eV), C-O (286.2 eV), C=O (287.8 eV) and O-C=O (289.0 eV).
Sources: en.wikipedia.org
2024 Conservative Party leadership election: Nominations open for the first round of the leadership election. July 2024 Welsh Labour leadership election: Eluned Morgan is elected unopposed as the new leader of Welsh Labour after nominations close at midday. The Senedd will be recalled on 6 August to choose a new First Minister of Wales following the resignation of Vaughan Gething and the subsequent Welsh Labour leadership election. 25 July – Conservative Party leadership election: Tom Tugendhat and Robert Jenrick enter the race to become the next Conservative leader. 26 July – Labour peer Lord Falconer introduces the Assisted Dying Bill into the House of Lords. The bill would allow anyone with a terminal illness and less than six months left to live to get medical assistance to end their life. Following a critical report on the Care Quality Commission, Health Secretary Wes Streeting describes the body as not fit for purpose. Conservative Party leadership election: Former Work and Pensions Secretary Mel Stride becomes the fourth candidate to announce his intention to run for the Conservative Party leadership election. 27 July – Conservative Party leadership election: Priti Patel becomes the fifth candidate to put their name forward for the election, standing as a unity candidate. 28 July – Labour accuses the previous Conservative government of "covering up" "catastrophic" problems in the public sector and creating a multi-billion pound gap in public finances.
All nuclear data not otherwise stated is from the standard source: There are 42 known isotopes of polonium (84Po), all radioactive, stretching from 186Po to 227Po. The isotopes 210 through 218 occur naturally in the four principal decay chains. In terms of curies they are mostly of even mass number, coming from uranium-238 and thorium-232, with smaller amounts of 211 and 215 from uranium-235, and very little with mass number 213 coming from neptunium-237, and much less with mass number 217 coming from a rare branch of the neptunium decay chain. 210Po has the longest half-life by far (138.376 days) and is, therefore, the most abundant by far in terms of moles or mass. It is also the most easily synthesized isotope, by neutron capture on natural bismuth, and so by far the most abundant artificial isotope as well. Two other isotopes have longer lives: 209Po with a half-life of 124 years and 208Po with a half-life of 2.898 years. Both are made by using a cyclotron to bombard bismuth with protons.
==== Determination by genetics or the environment ==== Behaviors can be either innate or learned from the environment, or both, dependent on the organism. The more complex nervous systems (or brains) are, the more influence learning has on behavior. However, even in mammals, a large fraction of behavior is genetically determined. For instance, prairie voles tend to be monogamous, while meadow voles are more promiscuous, a difference that is strongly determined by a single gene, Avpr1a, encoding a receptor for the peptide hormone Vasopressin.
NOS Journaal, a radio news bulletin that is broadcast every hour on the public broadcasting channels NPO Radio 1, NPO Radio 2, NPO Radio 4 and NPO Radio 5. NOS Headlines, a radio news bulletin especially made for a younger audience (like Newsbeat on BBC Radio 1), broadcast on NPO 3FM and NPO FunX. Since 2011 NOS op 3. NOS Radio 1 Journaal, a news and current affairs programme that is broadcast mornings and afternoons on NPO Radio 1. NOS Langs de lijn (Along the sideline), a sports programme on NPO Radio 1, featuring live sports coverage and results from the Eredivisie and other major sports. NOS Met het Oog op Morgen (With a view to tomorrow), a late-night current affairs programme on NPO Radio 1.
=== Hoechst stains === Hoechst is a bis-benzimidazole derivative compound that binds to the minor groove of DNA. Often used in fluorescence microscopy for DNA staining, Hoechst stains appear yellow when dissolved in aqueous solutions and emit blue light under UV excitation. There are two major types of Hoechst: Hoechst 33258 and Hoechst 33342. The two compounds are functionally similar, but with a little difference in structure. Hoechst 33258 contains a terminal hydroxyl group and is thus more soluble in aqueous solution, however this characteristics reduces its ability to penetrate the plasma membrane. Hoechst 33342 contains an ethyl substitution on the terminal hydroxyl group (i.e. an ethylether group) making it more hydrophobic for easier plasma membrane passage
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.